Diasorin

Director's Dealing • Dec 22, 2025

{0}------------------------------------------------

Informazione Regolamentata n. 0957-60-2025

Data/Ora Inizio Diffusione 22 Dicembre 2025 17:36:24 Euronext Milan

Societa' : DIASORIN

Utenza - referente : DIASORINN01 - Ulisse Spada - Valerio

Vaccarone

Tipologia : REGEM

Data/Ora Ricezione : 22 Dicembre 2025 17:36:24

Data/Ora Inizio Diffusione : 22 Dicembre 2025 17:36:24

Oggetto : Diasorin S.p.A. - 2026 Annual Calendar of

Corporate Events

Testo del comunicato

See in attachment.

{1}------------------------------------------------

DIASORIN S.P.A. - 2026 ANNUAL CALENDAR OF CORPORATE EVENTS

Saluggia, - December 22, 2025 – Diasorin S.p.A. (the "Company") hereby announces the corporate event calendar for fiscal year 2026.

Board of Directors

March 20, 2026	Draft Statutory Financial Statements 2025 and Consolidated Financial Statements 2025 approval
May 7, 2026	First Quarter 2026 results approval
July 31, 2026	Half-Yearly Financial Report approval
November 6, 2026	Third Quarter 2026 results approval

Shareholders' Meeting

	Annual General Meeting for: (i) 2025 Statutory Financial
April 29, 2026	Statements approval; (ii) Report on the remuneration policy and fees paid approval.

Indicative dates subject to change. Any changes will be communicated without delay.

The Company informs that the month envisaged for the payment of any dividend in relation to 2025 results is May 2026.

The information herein reported is given for the exclusive purpose of complying with the relevant Borsa Italiana regulations and cannot be interpreted or considered in any way as a forecast on the occurrence of the requirements for the distribution of dividends.

About DiaSorin

Headquartered in Italy and listed at the Italian Stock Exchange in the FTSE MIB Index, DiaSorin is a global leader in the In Vitro Diagnostic (IVD) field and is active since 2021 in the Life Science business. For over 50 years, the Company has been developing, producing and marketing reagent kits used by diagnostic laboratories worldwide.

The Group operates in 5 continents through 30 companies, 4 branches, 10 manufacturing facilities and 9 research and development centers. The extensive diagnostic testing and Life Science offer, made available through continuous investments in research, positions DiaSorin as the player with the broadest range of specialty tests available within the diagnostic market, and identifies the Group as the "Diagnostic Specialist".

More info at www.diasorin.com

FOR ADDITIONAL INFORMATION, PLEASE CONTACT:

INVESTOR RELATIONS

Riccardo Fava Eugenia Ragazzo

{2}------------------------------------------------

Corporate VP Communication, ESG & Investor Relations Corporate Investor Relations & ESG Analyst riccardo.fava@diasorin.it eugenia.ragazzo@diasorin.it

{3}------------------------------------------------

Fine Comunicato n.0957-60-2025 Numero di Pagine: 4